ARTICLE | Product Development
Sanofi, AZ pave the way for new RSV mAb with long-lasting protection data
Nirsevimab’s durability of effect, pricing model could make the therapy a game changer for RSV
July 30, 2020 6:27 AM UTC
Updated on Jul 30, 2020 at 5:31 PM UTC
Sanofi and AstraZeneca are on track to deliver an RSV-preventing mAb that would be more accessible and possibly more effective than Synagis in infants.
In a New England Journal of Medicine paper published on Wednesday, the companies showed that nirsevimab (MEDI 8897) provided at least five months of protection against respiratory syncytial virus RSV in preterm infants...